Clinical trials for Diabetes Mellitus Type 2

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44394 clinical trials with a EudraCT protocol, of which 7406 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (1,748)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

1,748 result(s) found for: Diabetes Mellitus Type 2. Displaying page 37 of 88.

EudraCT Number: 2008-007664-42

Sponsor Protocol Number: GLP112757

Start Date*: 2009-09-14

Sponsor Name:GlaxoSmithKline LLC

Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glim...

Medical condition: Type 2 Diabetes Mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	100000004861	10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2006-005383-51

Sponsor Protocol Number: H7U-MC-IDAZ

Start Date*: 2007-01-12

Sponsor Name:Lilly S.A.

Full Title: A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared with Once-Daily Insulin Glargine in Insulin-Naïve Patients with Type 2 ...

Medical condition: Type II diabetes

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed)

Trial results: View results

EudraCT Number: 2013-002348-99

Sponsor Protocol Number: AUTH88622

Start Date*: 2014-09-22

Sponsor Name:Aristotle University Thessaloniki

Full Title: A randomised, double blind, placebo-controlled study of the effect of liraglutide on arterial blood pressure in hypertensive patients with type 2 diabetes mellitus

Medical condition: Hypertention, Type 2 Diabetes

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.0	10047065 - Vascular disorders	10020772	Hypertension	PT
	17.0	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: GR (Completed)

Trial results: View results

EudraCT Number: 2009-016525-34

Sponsor Protocol Number: 28431754DIA3006

Start Date*: 2010-04-21

Sponsor Name:Janssen-Cilag International NV

Full Title: A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with...

Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	12.1		10067585	Type 2 diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: LV (Completed) BG (Completed) PT (Prematurely Ended) PL (Completed) SK (Completed) CZ (Completed) EE (Completed) SE (Completed) GR (Completed) IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2012-002422-78

Sponsor Protocol Number: 1

Start Date*: 2013-10-14

Sponsor Name:University of Leicester

Full Title: Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial.

Medical condition: Type 2 Diabetes Mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2014-004599-49

Sponsor Protocol Number: MB102-230

Start Date*: 2015-08-31

Sponsor Name:AstraZeneca AB

Full Title: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type...

Medical condition: Type 1 Diabetes Mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	10027433 - Metabolism and nutrition disorders	10067584	Type 1 diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed) GB (Completed) DE (Completed) NL (Completed) PL (Completed) BE (Completed)

Trial results: View results

EudraCT Number: 2013-001140-61

Sponsor Protocol Number: GWDM1302

Start Date*: 2013-12-30

Sponsor Name:GW Research Ltd.

Full Title: A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes.

Medical condition: Type 2 diabetes

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2009-014958-16

Sponsor Protocol Number: I2Q-MC-GMAH

Start Date*: 2010-01-15

Sponsor Name:Lilly S.A.

Full Title: A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients with Type 2 Diabetes Mellitus Treated with Diet and Exercise, with or without Metformin Estudio de fa...

Medical condition: diabetes mellitus tipo 2

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9		10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed)

Trial results: View results

EudraCT Number: 2019-000595-42

Sponsor Protocol Number: ESR-18-13834

Start Date*: 2019-07-08

Sponsor Name:Steno Diabetes Center Copenhagen

Full Title: A randomized, double-blind, placebo controlled, parallel, multicentre study of the effects of 12-weeks of sodium zirconium cyclosilicate (Lokelma) on albuminuria (UACR) in patients with diabetes an...

Medical condition: Treatment for proteinuria in type 1 or type 2 diabetes with hyperkalemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10027433 - Metabolism and nutrition disorders	10012601	Diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Prematurely Ended)

Trial results: View results

EudraCT Number: 2020-000763-23

Sponsor Protocol Number: ANJ900D3501

Start Date*: 2021-12-28

Sponsor Name:Anji Pharma (US) LLC

Full Title: A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Comparator-Controlled Study to Compare the Glycemic Effects, Safety, and Tolerability of Metformin Hydrochloride Delayed-Releas...

Medical condition: Type 2 Diabetes Mellitus with varying renal function from normal up to CKD3B

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004861	10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) PL (Completed) BG (Completed) HU (Completed)

Trial results: (No results available)

EudraCT Number: 2008-008127-15

Sponsor Protocol Number: 1264.3

Start Date*: 2010-07-16

Sponsor Name:Boehringer Ingelheim RCV Gmbh

Full Title: A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with p...

Medical condition: type 2 diabetes mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: LV (Completed) DE (Completed) EE (Completed) ES (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2008-002205-40

Sponsor Protocol Number: OTX115495 (DEFEND-1 EU)

Start Date*: 2008-08-29

Sponsor Name:Tolerx, Inc. [...]

Full Title: DEFEND-1: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes

Medical condition: Otelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are cu...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10027433 - Metabolism and nutrition disorders	10012608	Diabetes mellitus insulin-dependent	LLT

Population Age: Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: SE (Completed) FI (Completed) GB (Completed) DE (Completed) DK (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2021-004226-30

Sponsor Protocol Number: ORA-D-013-2

Start Date*: 2022-03-22

Sponsor Name:Oramed Ltd.

Full Title: A Double-Blinded, Placebo-controlled, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic C...

Medical condition: Type 2 Diabetes Mellitus (T2DM)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004861	10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2014-000988-41

Sponsor Protocol Number: UoL000977

Start Date*: 2014-08-22

Sponsor Name:University of Liverpool

Full Title: A randomized, controlled multi-centre trial of 26 weeks of subcutaneous Liraglutide (a GLP1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with Type 2 Di...

Medical condition: Obstructive Sleep Apnoea and Type 2 Diabetes

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000014722	10029983	Obstructive sleep apnoea syndrome	LLT
	20.0	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2017-003197-13

Sponsor Protocol Number: ISIS484137-CS2

Start Date*: 2017-11-24

Sponsor Name:Ionis Pharmaceuticals, Inc.

Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (ISIS-DGAT2RX, an Antisense Inhibitor of Diacylglycerol Acyltr...

Medical condition: Hepatic Steatosis in type 2 diabetes (T2DM)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT
	20.0	10019805 - Hepatobiliary disorders	10019708	Hepatic steatosis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed)

Trial results: View results

EudraCT Number: 2012-000671-16

Sponsor Protocol Number: BC28027

Start Date*: 2013-02-06

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities

Medical condition: - Stable Cardiovascular Disease and - Diabetes Mellitus Type 2 or Pre-diabetes

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT
	14.1	100000004849	10007648	Cardiovascular disease, unspecified	LLT
	14.1	10027433 - Metabolism and nutrition disorders	10036481	Pre-diabetes	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended)

Trial results: View results

EudraCT Number: 2016-000515-32

Sponsor Protocol Number: 2016-623

Start Date*: 2016-04-12

Sponsor Name:Per Løgstrup Poulsen

Full Title: Antiplatelet and vascular effects of aspirin in healthy persons and patients with type 2 diabetes.

Medical condition: Type 2 diabetes and Healthy volunteers

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	100000004861	10012594	Diabetes	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2015-005691-26	Sponsor Protocol Number: 201501252	Start Date*: 2016-07-14
Sponsor Name:University Medical Center Groningen
Full Title: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation
Medical condition: Type 1 diabetes with albuminuria
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: NL (Ongoing) DK (Completed)
Trial results: View results

EudraCT Number: 2014-000881-23

Sponsor Protocol Number: MYL-GAI-3002

Start Date*: 2014-10-28

Sponsor Name:MYLAN GmbH

Full Title: AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 2 DIABETES MELLITUS PATIENTS

Medical condition: Type 2 Diabetes mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.1	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Completed)

Trial results: View results

EudraCT Number: 2022-001906-24

Sponsor Protocol Number: LAMA/2021/1

Start Date*: 2022-11-14

Sponsor Name:Medical University in Lodz

Full Title: LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial .

Medical condition: Patients with ADHD and type I diabetes.

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	10037175 - Psychiatric disorders	10068453	ADHD, predominantly inattentive type	LLT
	21.1	10027433 - Metabolism and nutrition disorders	10067584	Type 1 diabetes mellitus	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: PL (Trial now transitioned)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Mon May 11 16:48:09 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA